Hiroshi Mochizuki

Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial

J. Charrow, M. Irving, K. White, 2020, The Lancet.

Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

J. Charrow, M. Irving, K. White, 2021, Genetics in Medicine.

Significance of glomerular IgM deposits in Children with idiopathic nephrotic syndrome

K. Joh, A. Katayama, T. Tsuda, 1994 .

Cerebral venous angioma Clinical reports on two cases

K. Hisanaga, H. Saito, Hiroshi Mochizuki, 1983 .

FUT2 non‐secretor status is associated with Type 1 diabetes susceptibility in Japanese children

K. Ihara, T. Ogata, Toshikazu Takahashi, 2017, Diabetic medicine : a journal of the British Diabetic Association.

Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.

J. Charrow, M. Irving, C. Bacino, 2023, The Lancet. Child & adolescent health.